Optiver Holding’s Regeneron Pharmaceuticals REGN Stock Holding History

Optiver Holding’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-183	Closed	-$141K	–	2661
2025 Q4	$141K	Buy	+183	New	+$124K	﹤0.01%	768
2025 Q2	–	Sell	-186	Closed	-$118K	–	1606
2025 Q1	$118K	Buy	+186	New	+$128K	﹤0.01%	441
2024 Q2	–	Sell	-214	Closed	-$206K	–	979
2024 Q1	$206K	Buy	+214	New	+$203K	﹤0.01%	474
2023 Q1	–	Sell	-3	Closed	-$2K	–	562
2022 Q4	$2K	Buy	+3	New	+$2.21K	﹤0.01%	426
2022 Q1	–	Sell	-109	Closed	-$66K	–	808
2021 Q4	$66K	Hold	109	–	–	﹤0.01%	368
2021 Q3	$66K	Buy	109 +84	+336%	+$52.1K	﹤0.01%	291
2021 Q2	$14K	Buy	+25	New	+$12.7K	﹤0.01%	413

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Optiver Holding's REGN Position: Q1 2026 in Review

Optiver Holding sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 183 shares — an estimated $141K sold.

Optiver Holding first reported a position in REGN in Q2 2021 and held it in 7 quarters. The position peaked at $206K in Q1 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Optiver Holding reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Optiver Holding sold 183 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $141K.
Optiver Holding first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Optiver Holding's Regeneron Pharmaceuticals position peaked at $206K in Q1 2024.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.